Niox Group PLC, which designs, develops and commercialises asthma devices, jumped 8% to 69p after an upbeat first-half trading update.
Revenue grew by roughly 22% to £18.8mln in the six months to 30 June 2023, while adjusted underlying earnings (EBITDA) nearly doubled to £6.2mln year-on-year.
"I am pleased to report continued growth in revenues and profits in the first half of the current financial year,” said executive chairman Ian Johnson.
“It is particularly satisfying to describe the strong growth in our core Clinical business, which continues to benefit from a high degree of recurring revenues.”